Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 19/20 | 1.00 |
| ▸ | CNR1 | P21554 | 9/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29989454 | 0.92 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL29362163 | 0.91 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL16344141 | 0.91 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL6324281 | 0.91 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL29989324 | 0.91 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL9035701 | 0.90 | CNR2 (0.81) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL10093010 | 0.89 | CNR2 (0.81) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL6325870 | 0.89 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL29988794 | 0.89 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 | |
| SCHEMBL6330271 | 0.87 | CNR2 (1.00) | CNR2CNR1MEN1NR1I2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739302-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | Cella Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| WO-2025085674-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ULCERATIVE COLITIS | BACAINN THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | WO | claimed |
| WO-2025010288-A2 | HYALURONIC ACID BASED DRUG DELIVERY SYSTEMS | VISUS THERAPEUTICS, INC. (US) | 2025-01-09 | — | — | WO | claimed |
| EP-3664795-B1 | CANNABIS AND DERIVATIVES THEREOF FOR THE TREATMENT OF PAIN AND INFLAMMATION RELATED WITH DENTAL PULP AND BONE REGENERATION RELATED TO DENTAL JAW BONE DEFECTS | CANNIBITE BVBA (BE) | 2024-06-19 | — | — | EP | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| CN-117100863-A | Use of cannabinoid systems and downstream pathways thereof for preventing and/or treating chronic itch | 南方科技大学 | 2023-11-24 | — | — | CN | claimed |
| US-20230181540-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | WYLDER NATION FOUNDATION | 2023-06-15 | — | — | US | claimed |
| EP-4153169-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | Wylder Nation Foundation (US) | 2023-03-29 | — | — | EP | claimed |
| WO-2022204414-A1 | FORMULATIONS AND KITS FOR THE DIAGNOSTIC EVALUATION OF INFECTIOUS DISEASES AND METHODS THEREOF | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| WO-2022204419-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. (US) | 2022-09-29 | — | — | WO | claimed |
| US-20220305147-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | VYRIPHARM ENTERPRISES, INC. | 2022-09-29 | — | — | US | claimed |
| US-20220117932-A1 | Lecithin Vesicles | CannaClear Inc. (CA) | 2022-04-21 | — | — | US | claimed |
| US-9289421-B2 | Methods and compositions for reducing serum levels of immunoglobulin E (IgE) | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-03-22 | — | — | US | claimed |
| US-20140350052-A1 | Methods and Compositions for Reducing Serum Levels of Immunoglobulin E (IGE) | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-11-27 | — | — | US | claimed |
| WO-2013033155-A1 | METHODS AND COMPOSITIONS FOR REDUCING SERUM LEVELS OF IMMUNOGLOBULIN E (IGE) | UNIVERSITY OF SOUTH FLORIA (US) | 2013-03-07 | — | — | WO | claimed |
| US-7763607-B2 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-07-27 | — | — | US | claimed |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | PHARMACIA CORPORATION | 2006-07-20 | — | — | US | claimed |
| WO-2004105699-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A CANNABINOID AGENT FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DAMAGE | PHARMACIA CORPORATION (US) | 2004-12-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR2 204/4885CNR1 221/4885MEN1 2211/4885 |
| US-20060160776-A1 | Compositions of a cyclooxygenase-2 selective inhibitor and a cannabinoid agent for the treatment of central nervous system damage | CNR2, CNR1, PTGS2 | CNR2 1/4885CNR1 2/4885MEN1 4616/4885 |
| US-20220305147-A1 | SYNTHETIC CANNABINOID COMBINATION THERAPY COMPOSITIONS AND METHODS FOR PERSONALIZED AND TARGETED THERAPIES INCLUDING THE TREATMENT OF INFECTIOUS DISEASES | CNR2, CNR1, FAAH | CNR2 1/4885CNR1 2/4885MEN1 1926/4885 |
| US-20230181540-A1 | COMPOSITIONS AND METHODS FOR ACTIVATING SIGNALING THROUGH THE CB2 CANNABINOID RECEPTOR FOR TREATING AND PREVENTING LYSOSOMAL STORAGE DISEASES AND DISORDERS | GBA1, CNR2, CNR1 | CNR2 2/4885CNR1 3/4885MEN1 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.